Trial
NCT04065841
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Non Alcoholic Steatohepatitis (NASH)
Intervention
Tropifexor
Why stopped
The sponsor made a business decision to stop development of the trial drugs. The decision to stop the trial early was not because of any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-28